Inicio>>Isotope-Labeled Compounds>> Deuterium>>Ethionamide-d3

Ethionamide-d3 (Synonyms: 2-ethylthioisonicotinamide-d3)

Catalog No.GC48947

Products are for research use only. Not for human use. We do not sell to patients.

Ethionamide-d3 Chemical Structure

Cas No.: 2748267-66-3

Tamaño Precio Disponibilidad Cantidad
500µg
221,00 $
Disponible
1mg
419,00 $
Disponible
5mg
1.438,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ethionamide-d3 is intended for use as an internal standard for the quantification of ethionamide by GC- or LC-MS. Ethionamide is an antimycobacterial compound that is active against M. tuberculosis (MICs = 0.3-1.25 µg/ml).1,2 It is activated via oxidation by flavin monooxygenase and inhibits the InhA enzyme involved in mycolic acid biosynthesis.1 Formulations containing ethionamide have been used in the second-line treatment of multi-drug resistant tuberculosis.

1.Laborde, J., Deraeve, C., and Bernardes-GÉnisson, V.Update of antitubercular prodrugs from a molecular perspective: Mechanisms of action, bioactivation pathways, and associated resistanceChemMedChem12(20)1657-1676(2017) 2.Heifets, L.B., Lindholm-Levy, P.J., and Flory, M.Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosisAm. Rev. Respir. Dis.143(2)268-270(1991)

Reseñas

Review for Ethionamide-d3

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ethionamide-d3

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.